We are live on ! Find out more
Balyasny Asset Management

Balyasny Asset Management Portfolio holdings

AUM $77.1B
1-Year Est. Return 42.89%
This Fund
S&P 500
This Quarter Est. Return
+7.45%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$32B
AUM Growth
+$6.48B
Cap. Flow
+$4.77B
Cap. Flow %
14.9%
Top 10 Hldgs %
10.84%
Holding
2,554
New
720
Increased
686
Reduced
602
Closed
529

Sector Composition

Rank Sector Weight
1 Financials 20.47%
2 Consumer Discretionary 12.5%
3 Healthcare 10.55%
4 Industrials 6.63%
5 Real Estate 6.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADXS
2001
DELISTED
Advaxis Inc
ADXS
$61K ﹤0.01%
1,429
+1
+0.1% +$51
GNMK
2002
DELISTED
GenMark Diagnostics, Inc
GNMK
$61K ﹤0.01%
+14,540
New +$87.5K
NVAX icon
2003
Novavax
NVAX
$1.27B
$60K ﹤0.01%
+2,400
New +$58.6K
BV
2004
DELISTED
Bazaarvoice, Inc.
BV
$58K ﹤0.01%
10,651
-14,100
-57% -$71.1K
BCRX icon
2005
BioCryst Pharmaceuticals
BCRX
$2.31B
$54K ﹤0.01%
11,091
-42,705
-79% -$207K
ATHX
2006
DELISTED
Athersys, Inc. Common Stock
ATHX
$54K ﹤0.01%
+1,198
New +$58K
KOPN icon
2007
Kopin
KOPN
$732M
$52K ﹤0.01%
+16,368
New +$56.4K
ICON
2008
DELISTED
Iconix Brand Group, Inc.
ICON
$52K ﹤0.01%
+4,046
New +$115K
NOG icon
2009
Northern Oil and Gas
NOG
$2.15B
$51K ﹤0.01%
+2,502
New +$30.2K
PACB icon
2010
Pacific Biosciences
PACB
$404M
$51K ﹤0.01%
19,296
-14,204
-42% -$49.7K
WKHS icon
2011
Workhorse Group
WKHS
$38.2M
$51K ﹤0.01%
7
CSLT
2012
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$50K ﹤0.01%
+13,400
New +$53.6K
GSAT icon
2013
Globalstar
GSAT
$10.7B
$48K ﹤0.01%
2,425
+365
+18% +$8.3K
PRKR
2014
DELISTED
Parkervision Inc
PRKR
$48K ﹤0.01%
+45,000
New +$60.3K
MCF
2015
DELISTED
Contango Oil & Gas Co.
MCF
$47K ﹤0.01%
+10,067
New +$38.5K
BDSI
2016
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$43K ﹤0.01%
+14,700
New +$40.6K
GNW icon
2017
Genworth Financial
GNW
$3.71B
$42K ﹤0.01%
13,532
-15,984
-54% -$55.3K
CFMS
2018
DELISTED
Conformis, Inc. Common Stock
CFMS
$40K ﹤0.01%
+676
New +$54K
INFI
2019
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$39K ﹤0.01%
+19,325
New +$40.1K
PDLI
2020
DELISTED
PDL BioPharma, Inc.
PDLI
$35K ﹤0.01%
+12,900
New +$39.6K
GST
2021
DELISTED
Gastar Exploration Inc.
GST
$25K ﹤0.01%
+24,157
New +$21K
EGLT
2022
DELISTED
Egalet Corporation
EGLT
$23K ﹤0.01%
+23,147
New +$24.9K
GEN
2023
DELISTED
Genesis Healthcare, Inc.
GEN
$12K ﹤0.01%
15,225
-14,705
-49% -$13.1K
AAOI icon
2024
Applied Optoelectronics
AAOI
$10.3B
-825,300
Closed -$36.4M
ABBV icon
2025
CALL
AbbVie
ABBV
$435B
-300,200
Closed -$26.7M

Similar funds

Balyasny Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Balyasny Asset Management held 2,554 positions worth $32B, up 25% from $25.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Balyasny Asset Management deployed $4.77B of net new capital in Q4 2017, opening 720 new positions and adding to 686 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 1,700,000 shares worth $148M.

By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was American Express, an estimated $253M trimmed.

  • Balyasny Asset Management's largest Q4 2017 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 1,700,000 shares worth $148M.
  • Balyasny Asset Management added most to Aetna Inc in Q4 2017, an estimated $175M increase.
  • Balyasny Asset Management's biggest Q4 2017 reduction was American Express, cutting an estimated $253M.
  • Balyasny Asset Management fully exited Range Resources in Q4 2017, selling an estimated $104M.
  • Balyasny Asset Management's ten largest holdings make up 11% of its $32B portfolio in Q4 2017.
  • Balyasny Asset Management opened 720 new positions and closed 529 in Q4 2017.
  • Balyasny Asset Management's portfolio value rose 25% quarter-over-quarter to $32B.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.